Synthesis and biological evaluation of 3-arylcoumarins as potential anti-Alzheimer's disease agents

References

• Burns A, Iliffe S. Alzheimer's disease. BMJ 2009;338:b158.
   PubMed Web of Science ®Google Scholar
• Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47.
   PubMed Web of Science ®Google Scholar
• Singh M, Kaur M, Kukreja H, et al. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 2013;70:165–88.
   PubMed Web of Science ®Google Scholar
• Furukawa-Hibi Y, Alkam T, Nitta A, et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behav Brain Res 2011;225:222–9.
   PubMed Web of Science ®Google Scholar
• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004;11:2033–43.
   PubMed Web of Science ®Google Scholar
• Knez D, Sova M, Košak U, et al. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease. Future Med Chem 2017;9:811–32.
   PubMed Web of Science ®Google Scholar
• Maria JM, Pérez-Cruz F, Saleta VR, et al. Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins. Bioorg Med Chem 2013;21:3900–6.
   PubMed Web of Science ®Google Scholar
• Pu WC, Lin Y, Zhang JS, et al. 3-Arylcoumarins: synthesis and potent anti-inflammatory activity. Bioorg Med Chem Lett 2014;24:5432–4.
   PubMed Web of Science ®Google Scholar
• Zhao HP, Yan B, Peterson LB, et al. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett 2012;3:327–31.
   PubMed Web of Science ®Google Scholar
• Nichols DB, Leão RAC, Basu A, et al. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors. Chem Biol Drug Des 2013;81:607–14.
   PubMed Web of Science ®Google Scholar
• ElSeedi HR. Antimicrobial Arylcoumarins from Asphodelus microcarpus. J Nat Prod 2007;70:118–20.
   PubMed Web of Science ®Google Scholar
• Wang B, Li N, Liu T, et al. Synthesis and biological evaluation of novel neoflavonoid derivatives as potential antidiabetic agents. RSC Adv 2017;7:34448–60.
   Web of Science ®Google Scholar
• Orhan IE, Gulcan HO. Coumarins: auspicious cholinesterase and monoamine oxidase inhibitors. Curr Top Med Chem 2015;15:1673–82.
   PubMed Web of Science ®Google Scholar
• Secci D, Carradori S, Bolasco A, et al. Synthesis and selective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin derivatives. Eur J Med Chem 2011;46:4846–52.
   PubMed Web of Science ®Google Scholar
• Wang ZM, Li XM, Xue GM, et al. Synthesis and evaluation of 6-substituted 3-arylcoumarin derivatives as multifunctional acetylcholinesterase/monoamine oxidase B dual inhibitors for the treatment of Alzheimer’s disease. RSC Adv 2015;5:104122–37.
   Web of Science ®Google Scholar
• Anand P, Singh B, Singh N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg Med Chem 2012;20:1175–80.
   PubMed Web of Science ®Google Scholar
• Pisani L, Farina R, Catto M, et al. Exploring basic tail modifications of coumarin-based dual acetylcholinesterase-monoamine oxidase B inhibitors: identification of water-soluble, brain-permeant neuroprotective multitarget agents. J Med Chem 2016;59:6791–806.
   PubMed Web of Science ®Google Scholar
• Najafi Z, Mahdavi M, Saeedi M, et al. Novel tacrine-coumarin hybrids linked to 1,2,3-triazole as anti-Alzheimer’s compounds: in vitro and in vivo biological evaluation and docking study. Bioorg Chem 2019;83:303–16.
   PubMed Web of Science ®Google Scholar
• Yang HL, Cai P, Liu QH, et al. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease. Eur J Med Chem 2017;138:715–28.
   PubMed Web of Science ®Google Scholar
• Pisani L, Farina R, Soto-Otero R, et al. Searching for multi-targeting neurotherapeutics against Alzheimer’s: discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-Chromen-2-one structural motif. Molecules 2016;21:362.
   PubMed Web of Science ®Google Scholar
• Patil PO, Bari SB, Firke SD, et al. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease. Bioorg Med Chem 2013;21:2434–50.
   PubMed Web of Science ®Google Scholar
• Matos MJ, Janeiro P, González Franco RM, et al. Synthesis, pharmacological study and docking calculations of new benzo[f] coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases. Future Med Chem 2014;6:371–83.
   PubMed Web of Science ®Google Scholar
• Brühlmann C, Ooms F, Carrupt PA, et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 2001;44:3195–8.
   PubMed Web of Science ®Google Scholar
• Alipour M, Khoobi M, Nadri H, et al. Synthesis of some new 3-coumaranone and coumarin derivatives as dual inhibitors of acetyl- and butyrylcholinesterase. Arch Pharm 2013;44:577–87.
   Web of Science ®Google Scholar
• Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.
   PubMed Web of Science ®Google Scholar
• Holt A, Sharman DF, Baker GB, et al. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 1997;244:384–92.
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Gross A, Finberg JPM. Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132:500–6.
   PubMed Web of Science ®Google Scholar
• Stafford GI, Pedersen PD, Jäger AK, et al. Monoamine oxidase inhibition by southern African traditional medicinal plants. S Afr J. Bot 2007;73:384–90.
   Web of Science ®Google Scholar
• Benzie IFF, Strain JJ. The Ferric Reducing Ability of Plasma (FRAP) as a measure of ‘‘Antioxidant Power’’: the FRAP assay. Anal Biochem 1996;239:70–6.
   PubMed Web of Science ®Google Scholar
• Hu YH, Wang B, Yang J, et al. Synthesis and biological evaluation of 3-arylcoumarin derivatives as potential antidiabetic agents. J Enzyme Inhib Med Chem 2019;34:15–30.
   PubMed Web of Science ®Google Scholar
• Asadipour A, Alipour M, Jafari M, et al. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem 2013;70:623–30.
   PubMed Web of Science ®Google Scholar
• Joubert J, Foka GB, Repsold BP, et al. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem 2017;125:853–64.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Kanetaka H, Hirose D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Disord Extra 2015;5:135–46.
   PubMed Web of Science ®Google Scholar
• Karlsson D, Fallarero A, Brunhofer G, et al. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur J Pharm Sci 2012;47:190–205.
   PubMed Web of Science ®Google Scholar
• Matos MJ, Viña D, Vazquez-Rodriguez S, et al. Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold. Curr Top Med Chem 2012;12:2210–39.
   PubMed Web of Science ®Google Scholar
• Kim D, Baik SH, Kang S, et al. Close correlation of monoamine oxidase activity with progress of alzheimer's disease in mice, observed by in vivo two-photon imaging. ACS Cent Sci 2016;2:967–75.
   PubMed Web of Science ®Google Scholar
• Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 2007;85:3036–40.
   PubMed Web of Science ®Google Scholar